Prostate Cancer Risk is lower in long-term lipid-lowering drugs users


Men who use lipid-lowering medication long term have a lower risk for prostate cancer (PCa) than nonusers, a new study suggests.

The Authors prospectively examined 6518 black and white men without PCa at baseline in the ARIC (Atherosclerosis Risk in Communities) study. Of these, 21% of white and 11% of black men received lipid-lowering medication, typically statins. During follow-up, PCa developed in 541 white and 259 black men, and 56 and 34, respectively, died.

Compared with men who never used lipid-lowering medications, those who used the drugs for 10 or more years had a significant 32% decreased risk for PCa in adjusted analyses. Current users of lipid-lowering drugs had a non-significant 33% decreased risk of dying from PCa than nonusers.

The findings generally corroborate previous studies on the subject. "Taken together, this literature provides strong evidence for a protective biologic mechanism of lower cholesterol on prostate cancer mortality.


Mondul AM, Joshu CE, Barber JR, et al. Longer-term lipid-lowering drug use and risk of incident and fatal prostate cancer in black and white Men in the ARIC study. Canc Prev Res.